leadf
logo-loader
viewHydrix Ltd
(
ASX:HYD
)

Hydrix and Memphasys' device for separating high-quality sperm from semen for IVF gets award

The companies have been recognised for design and engineering excellence at the Good Design Awards.

Hydrix Ltd - Hydrix and Memphasys' device for separating high-quality sperm from semen for IVF gets award
The Felix device consists of a console and single-use cartridges

Hydrix Ltd (ASX:HYD) and bio-separations company Memphasys Ltd (ASX:MEM) have jointly received two 2020 Good Design Awards for the Felix device, used for quickly separating high-quality sperm from semen sample for use in human IVF (In vitro fertilisation) procedures.

The Felix device has received a Gold Good Design Award for engineering design and a Good Design Award for product design in the medical and scientific category.

Australia’s annual Good Design Awards program is one of the oldest and most prestigious international design awards in the world, promoting excellence in design and innovation since 1958.

Transforming disruptive medical ideas into products

Hydrix executive chairman Gavin Coote said: “These Good Design awards demonstrate the powerful product innovation capability that Hydrix uses to help clients transform disruptive medical ideas into commercial products.

“We are thrilled to apply our innovation, creativity, and product engineering excellence to help Memphasys become a great Australian technology company success story."

Felix device

The Felix device consists of a console and single-use cartridges containing the cell-separation technology.

Hydrix’s role in the project was to translate Memphasys’s core technology into a usable, commercial product, applying its user experience (UX), industrial design and engineering skills. 

Quick facts: Hydrix Ltd

Follow
ASX:HYD

Price: 0.145 AUD

Market Cap: $23.8 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Hydrix Limited hails US FDA approval for AngelMed's Guardian device

  Hydrix Limited's (ASX:HYD) Gavin Coote speaks to Proactive's Andrew Scott soon after announcing the US Food and Drug Administration has approved the upgraded battery for the AngelMed Guardian device for commercial release in the USA. He says the Guardian is the world’s only implantable...

on 30/6/21

2 min read